Related Experiment Video
Updated: May 12, 2026
10:36
Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Probiotic administration in congenital heart disease: a pilot study
C L Ellis1, N A Bokulich, K M Kalanetra
1Department of Internal Medicine, University of California Davis, Davis, CA 95817, USA.
Summary
Probiotic Bifidobacterium longum ssp. infantis did not alter the gut microbiota in infants with congenital heart disease. While some plasma cytokines showed transient changes, the overall impact was inconsistent, suggesting further research is needed.
Area of Science:
- Neonatal immunology
- Microbiome research
- Pediatric cardiology
Background:
- Congenital heart disease (CHD) in infants is linked to gut dysbiosis.
- The gut microbiome plays a crucial role in immune system development.
- Understanding microbial and immune alterations in CHD is vital for therapeutic interventions.
Purpose of the Study:
- To assess the effect of probiotic Bifidobacterium longum ssp. infantis (B. infantis) on fecal microbiota composition in neonates with CHD.
- To evaluate the impact of B. infantis supplementation on plasma cytokine profiles in these infants.
Main Methods:
- A randomized, placebo-controlled trial involving 16 infants with CHD.
- Infants received either B. infantis or placebo for 8 weeks.
- Fecal microbial composition and weekly plasma cytokine levels (IL-10, IFN-γ, IL-1β) were analyzed.
Main Results:
- Infants with CHD exhibited altered fecal microbiota compared to healthy controls, but B. infantis did not significantly change microbial composition in CHD infants.
- Plasma levels of interleukin-10 (IL-10), interferon-gamma (IFN-γ), and interleukin-1beta (IL-1β) were transiently elevated in the probiotic group.
- No significant differences in fecal microbiota were observed between the probiotic and placebo groups.
Conclusions:
- Infants with CHD experience gut dysbiosis.
- Probiotic B. infantis supplementation did not significantly alter the fecal microbiota in neonates with CHD.
- Observed changes in plasma cytokines were inconsistent, indicating a limited impact of the probiotic on the measured immune markers.
Related Concept Videos
01:22Probiotics
Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
01:28Development of the Oral Microbiota
The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
01:30Development of Human Microbiota
The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...